Skip to main content

Table 1 Basal and operative characteristics of patients enrolled into the study

From: Impact of epicardial ablation of concomitant atrial fibrillation on atrial natriuretic peptide levels and atrial function in 6 months follow-up: does preoperative ANP level predict outcome of ablation?

  AF ablation group (n = 42) AF control group without ablation (n = 16) SR control group (n = 20) p-value
Demography     
  Age [years] 71.3 ± 8.3 73.8 ± 6.6 68.9 ± 7.0 0.16
  Male gender, n (%) 31 (73,8%) 12 (75%) 15 (75%) 0.99
  Body Mass Index (kg/m2) 29.4 (5.3) 27.5 (4.9) 29.2 (3.9) 0.38
AF duration [months] 64.8 ± 57.1 73.0 ± 92.9 0 0.291
Type of AF %, (n)     
HRS/AHA (ACC: initial reclassified initial reclassified   
  1. Paroxysmal 11.9% 11.9% (5) 25.0% 25.0% (4) 0  
  2. Persistent 23.8% 23.8% (10) 31.2% 31.2% (5) 0  
  3. Longstanding pers. 21.4% 64.3% (27) 12.5% 43.7% (7) 0  
  4. Permanent 42.9% ------ 31.2% ------ 0  
Cox - classification:     
  Intermittent 35.7% (15) 56.2% (9) 0 0.231
  Continuous 64.3% (27) 43.7% (7) 0 0.231
Preop. cardioversion (DC), n (%) 11 (26.2%) 5 (31.2%) 1 (5%)  
Preop. catheter ablation, n (%) 2 (4.8%) 0 0  
Preop. perm. anticoagulation, n (%) 26 (61.9%) 9 (56.2%) 1 (5%)  
Previous cardiac surgery 0 3 (18.75%) 0  
Comorbidity, n (%)     
Stroke 6 (14.3%) 2 (12.5%) 1 (5%)  
Heart failure (CHF) 25 (59.5%) 10 (62.5%) 7 (35%)  
Myocardial infarction 12 (28.6%) 5 (31.3%) 7 (35%)  
Pre-op. creatinine [mg/dl] 1.3 ± 0.32 1.29 ± 0.35 1.09 ± 0.28 0.13
ECHO data     
  EF (Simpson) [%] 54.1 ± 10.8 54.1 ± 14.4 61.0 ± 9.0 0.07
  Max. LA area [cm2] 27.7 (24.1-32.4) 27.8 (23.5-30.4) 20.3 (14.7-24.6) 0.651 , p < 0.001 2
  Max. LA diameter (LAD) [mm] 48.5 ± 7.0 47.5 ± 7.2 41.7 ± 6.5 0.651 , p < 0.01 2
  LA AFF [%] 0 (0–25.2) 0 (0–34.9) 43.2 (32.4-52.8) p > 0.051 , p < 0.001 2
Procedures     
Without mitral-surg., n (%) 32 (76%) 12 (75%) 18 (90%) 1.01,20.372
  CABG 12 (28.6%) 2 (12.5%) 13 (65%)  
  AVR 7 (16.7%) 3 (18.75%) 5 (25%)  
  Aortic replacement 1 (2.3%) - -  
  AVR + CABG 11 (26.2%) 3 (18.75%) -  
  AVR + Aortic replacement - 2 (12.5%)   
  Aortic replacement + CABG 1 (2.3%)   -  
  Tricuspid valve surgery - 1 (6.25%) -  
  VSD - 1 (6.25%) -  
With mitral-surgery, n (%) 10 (23.8%) 4 (25%) 2 (10%) 1.01, 0.372
Euroscore II (%) 3.0 ± 2.36 4.3 ± 3.15 1.94 ± 1.54 0.007 2
LAA Amputation, n (%) 9 (21.4%) 2 (12.5%) 1 (5%)  
RAA Amputation, n (%) 42 (100%) 16 (100%) 20 (100%)  
  1. Abbreviations comment: AF atrial fibrillation, SR sinus rhythm, LA left atrium, AFF atrial filling fraction, AVR aortic valve replacement, VSD ventricular septal defect, MV mitral valve, MVR mitral valve replacement, LAA left atrial appendage, RAA right atrial appendage; 1represents the differences between AF ablation group and AF control group without ablation; 2represents the differences between AF ablation group vs SR control group and AF control group without ablation vs SR control group. Values are demonstrated as mean ± SD or median (25–75 percentiles).